Kestra Private Wealth Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Kestra Private Wealth Services’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$229K	Sell	8,729 -3,000	-26%	-$69.9K	﹤0.01%	1620
2026 Q1	$276K	Sell	11,729 -6,105	-34%	-$156K	﹤0.01%	1491
2025 Q4	$518K	Sell	17,834 -1,032	-5%	-$26.4K	0.01%	1145
2025 Q3	$356K	Sell	18,866 -2,416	-11%	-$38.1K	﹤0.01%	1270
2025 Q2	$298K	Buy	21,282 +7,124	+50%	+$99.9K	﹤0.01%	1283
2025 Q1	$221K	Buy	+14,158	New	+$199K	﹤0.01%	1343

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Kestra Private Wealth Services's ARQT Position: Q2 2026 in Review

Kestra Private Wealth Services reduced its Arcutis Biotherapeutics (ARQT) stake by 26% in Q2 2026, selling an estimated $69.9K and leaving 8,729 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

Kestra Private Wealth Services first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. The position peaked at $518K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Kestra Private Wealth Services held 8,729 shares of Arcutis Biotherapeutics worth $229K as of Q2 2026.
Kestra Private Wealth Services sold 3,000 Arcutis Biotherapeutics shares in Q2 2026, an estimated $69.9K.
Arcutis Biotherapeutics made up ﹤0.01% of Kestra Private Wealth Services's portfolio in Q2 2026, its #1620 holding.
Kestra Private Wealth Services first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
Kestra Private Wealth Services's Arcutis Biotherapeutics position peaked at $518K in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Kestra Private Wealth Services's 13F filing for Q2 2026, filed 28 Jul 2026.